F2RL1 and cancer: This study supports the idea that both PAR2 agonists and antagonists might have valuable therapeutic roles in different tissues and encourages the development of both agonists and especially antagonists that are selective for PAR2 as potential new therapies for cancers and inflammatory conditions.